Association between RAAS Antagonism and COVID-19-related Mortality in Patients with Overweight/Obesity-related Hypertension: A Retrospective Cohort Study.
Elham ShamsVijayvardhan KamalumpundiLinhai ChengAdeyinka TaiwoAmal Shibli-RahhalAyotunde O DokunMarcelo Lima de Gusmão CorreiaPublished in: Arquivos brasileiros de cardiologia (2023)
Results suggest that hospitalized patients with COVID-19 and overweight/obesity-related hypertension who were prescribed ARB/ACEI before admission to the hospital exhibit lower mortality and less severe COVID-19 than those who were not taking ARB/ACEI. The results also suggest that exposure to ARB/ACEI may protect patients with overweight/obesity-related hypertension from severe COVID-19 and death.